Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 17

1.

Phosphodiesterase 4 inhibition enhances the dopamine D1 receptor/PKA/DARPP-32 signaling cascade in frontal cortex.

Kuroiwa M, Snyder GL, Shuto T, Fukuda A, Yanagawa Y, Benavides DR, Nairn AC, Bibb JA, Greengard P, Nishi A.

Psychopharmacology (Berl). 2012 Feb;219(4):1065-79. doi: 10.1007/s00213-011-2436-8. Epub 2011 Aug 11.

2.

Potential for targeting dopamine/DARPP-32 signaling in neuropsychiatric and neurodegenerative disorders.

Nishi A, Shuto T.

Expert Opin Ther Targets. 2017 Mar;21(3):259-272. doi: 10.1080/14728222.2017.1279149. Epub 2017 Jan 13. Review.

PMID:
28052701
3.

PET measurements of cAMP-mediated phosphodiesterase-4 with (R)-[11C]rolipram.

Kenk M, Thomas A, Lortie M, Dekemp R, Beanlands RS, Dasilva JN.

Curr Radiopharm. 2011 Jan;4(1):44-58. Review.

PMID:
22191614
4.

DARPP-32: from neurotransmission to cancer.

Belkhiri A, Zhu S, El-Rifai W.

Oncotarget. 2016 Apr 5;7(14):17631-40. doi: 10.18632/oncotarget.7268. Review.

5.

PDE4D phosphorylation: A coincidence detector integrating multiple signaling pathways.

Mika D, Conti M.

Cell Signal. 2016 Jul;28(7):719-24. doi: 10.1016/j.cellsig.2015.11.001. Epub 2015 Nov 10. Review.

PMID:
26562185
6.

PDE4 as a target for cognition enhancement.

Richter W, Menniti FS, Zhang HT, Conti M.

Expert Opin Ther Targets. 2013 Sep;17(9):1011-27. doi: 10.1517/14728222.2013.818656. Epub 2013 Jul 25. Review.

7.

Disrupted in schizophrenia 1 and phosphodiesterase 4B: towards an understanding of psychiatric illness.

Millar JK, Mackie S, Clapcote SJ, Murdoch H, Pickard BS, Christie S, Muir WJ, Blackwood DH, Roder JC, Houslay MD, Porteous DJ.

J Physiol. 2007 Oct 15;584(Pt 2):401-5. Epub 2007 Sep 6. Review.

8.

The involvement of DARPP-32 in the pathophysiology of schizophrenia.

Wang H, Farhan M, Xu J, Lazarovici P, Zheng W.

Oncotarget. 2017 Apr 21;8(32):53791-53803. doi: 10.18632/oncotarget.17339. eCollection 2017 Aug 8. Review.

9.

Targeting the dopamine D1 receptor in schizophrenia: insights for cognitive dysfunction.

Goldman-Rakic PS, Castner SA, Svensson TH, Siever LJ, Williams GV.

Psychopharmacology (Berl). 2004 Jun;174(1):3-16. Epub 2004 Apr 30. Review.

PMID:
15118803
10.

Prefrontal cortical network connections: key site of vulnerability in stress and schizophrenia.

Arnsten AF.

Int J Dev Neurosci. 2011 May;29(3):215-23. doi: 10.1016/j.ijdevneu.2011.02.006. Epub 2011 Feb 21. Review.

11.

Prefrontal DA transmission at D1 receptors and the pathology of schizophrenia.

Abi-Dargham A, Moore H.

Neuroscientist. 2003 Oct;9(5):404-16. Review.

PMID:
14580124
12.

[Role of Cdk5 in dopamine signaling and addiction].

Nishi A.

Tanpakushitsu Kakusan Koso. 2009 Jun;54(7):813-9. Review. Japanese. No abstract available.

PMID:
19514267
13.

Phosphodiesterase-4 (PDE4) molecular pharmacology and Alzheimer's disease.

Gurney ME, D'Amato EC, Burgin AB.

Neurotherapeutics. 2015 Jan;12(1):49-56. doi: 10.1007/s13311-014-0309-7. Review.

14.

A behavioral genetics approach to understanding D1 receptor involvement in phasic dopamine signaling.

Wall VZ, Parker JG, Fadok JP, Darvas M, Zweifel L, Palmiter RD.

Mol Cell Neurosci. 2011 Jan;46(1):21-31. doi: 10.1016/j.mcn.2010.09.011. Epub 2010 Oct 1. Review.

15.
16.

Molecular mechanisms of stress-induced prefrontal cortical impairment: implications for mental illness.

Hains AB, Arnsten AF.

Learn Mem. 2008 Aug 6;15(8):551-64. doi: 10.1101/lm.921708. Print 2008 Aug. Review.

PMID:
18685145
17.

Phosphodiesterase Inhibition and Regulation of Dopaminergic Frontal and Striatal Functioning: Clinical Implications.

Heckman PR, van Duinen MA, Bollen EP, Nishi A, Wennogle LP, Blokland A, Prickaerts J.

Int J Neuropsychopharmacol. 2016 Apr 30. pii: pyw030. doi: 10.1093/ijnp/pyw030. [Epub ahead of print] Review.

Supplemental Content

Support Center